JGC
MYGN icon

J. Goldman & Co’s Myriad Genetics MYGN Stock Holding History

J. Goldman & Co’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-35,624
Closed -$957K – 298
2013
Q2 		$957K Buy
+35,624
New +$1.03M 0.1% 186

Other funds holding MYGN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
MNA
Manning & Napier Advisors Fairport, New York $7.09B AUM 17.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MCM
Munder Capital Management Birmingham, Michigan $13.4B AUM 18.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.28B AUM 23.15% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

J. Goldman & Co's MYGN Position: Q3 2013 in Review

J. Goldman & Co sold out of Myriad Genetics (MYGN) in Q3 2013, closing a stake of 35,624 shares — an estimated $957K sold.

J. Goldman & Co first reported a position in MYGN in Q2 2013 and held it in 1 quarter. The position peaked at $957K in Q2 2013. 267 funds tracked by Wall St. Rank hold MYGN as of Q3 2013.

  • J. Goldman & Co reported no remaining Myriad Genetics position as of Q3 2013 after selling out during the quarter.
  • J. Goldman & Co sold 35,624 Myriad Genetics shares in Q3 2013, an estimated $957K.
  • J. Goldman & Co first reported a position in Myriad Genetics in Q2 2013 and held it in 1 quarter.
  • J. Goldman & Co's Myriad Genetics position peaked at $957K in Q2 2013.
  • 267 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2013.

Based on J. Goldman & Co's 13F filing for Q3 2013, filed 14 Nov 2013.